Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-39393406 · 2 trials · 2 indications
Brief Assessment of Cognition (BACS)
| Arm | Type | Description |
|---|---|---|
| JNJ-39393406 | EXPERIMENTAL | 2 capsules, once daily for the first week and 4 capsules once a day for the rest of the trial. |
| Placebo | PLACEBO_COMPARATOR | 2 capsules, once daily for the first week and 4 capsules once a day for the rest of the trial. |
| Name | Type | Description |
|---|---|---|
| JNJ-39393406 | DRUG | JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial |
| Placebo | DRUG | JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial |
Inclusion Criteria: 1. Meet DSM V criteria for history of MDD or BPD by MINI. 2. Between 18-50 years of age, male or female subjects of any race, smokers and non-smokers. 3. Able to provide informed consent. All participant patients must have signed an informed consent document indicating they unde...
JNJ-39393406 is an investigational small molecule being developed by Johnson & Johnson for depression. It is a positive allosteric modulator of CHRNA7, the alpha-7 nicotinic acetylcholine receptor. It has been studied in early-stage clinical trials, including a Phase 2 study in depression and a Phase 1 pharmacokinetic study in healthy volunteers.
JNJ-39393406 is being studied for depression. A completed Phase 2 trial evaluated its effects on psychometric performance and residual depressive symptoms in adults with depression. It is investigational and has not been approved for any indication.
JNJ-39393406 targets CHRNA7, the gene encoding the alpha-7 nicotinic acetylcholine receptor. It acts as a positive allosteric modulator, meaning it enhances receptor activity rather than directly activating the receptor itself. This mechanism is being explored in the context of depression.
JNJ-39393406 is being developed by Johnson & Johnson, which trades on the New York Stock Exchange under the ticker JNJ. The compound, also known as JNJ 39393406, is part of the company's psychiatry pipeline.
JNJ-39393406 is in Phase 1 development overall, though it has also been tested in a Phase 2 trial. It is investigational and has not received FDA approval. Two trials have been completed, and no trials are currently active.
JNJ-39393406 has been studied in two completed trials. NCT02677207 was a Phase 2 trial of 80 participants with depression in Moldova and Romania. NCT01556217 was a Phase 1 pharmacokinetic study of 12 healthy volunteers aged 50 and older, examining cerebrospinal fluid levels.
Yes, JNJ-39393406 and JNJ 39393406 refer to the same investigational compound. The 30 mg solution is a specific formulation used in studies. All of these names identify the same CHRNA7 positive allosteric modulator being developed by Johnson & Johnson for depression.